Cover Image
市場調查報告書

皮膚炎 - 開發中產品分析

Skin Inflammation - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 251585
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
皮膚炎 - 開發中產品分析 Skin Inflammation - Pipeline Review, H1 2014
出版日期: 2014年02月28日 內容資訊: 英文 42 Pages
簡介

皮膚炎是受到蚊蟲咬傷、過敏,或是刺激等與年齡、性別無關而可能引發的一種疾病。症狀五花八門,會因過敏反應、細菌感染、藥物反應、外傷、真菌感染、病毒感染、濕疹、蕁麻疹等原因造成。

本報告提供皮膚炎的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

皮膚炎概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/實驗室別

開發中產品的概要

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • Med Discovery SA
  • Kineta, Inc.
  • Neopharm Co., Ltd.
  • vida therapeutics inc.

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ShK-186
  • MDPK-67b
  • MSX-122
  • V-2248
  • OA-1
  • NPS-3
  • NPS-4 - Drug Profile

開發中產品的最新趨勢

暫停中的計劃

產品開發的里程碑

  • 熱門資訊和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC4645IDB

Global Markets Direct's, 'Skin Inflammation - Pipeline Review, H1 2014', provides an overview of the Skin Inflammation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Skin Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Skin Inflammation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Skin Inflammation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Skin Inflammation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Skin Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Skin Inflammation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Skin Inflammation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Skin Inflammation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Skin Inflammation Overview
  • Therapeutics Development
    • Pipeline Products for Skin Inflammation - Overview
    • Pipeline Products for Skin Inflammation - Comparative Analysis
  • Skin Inflammation - Therapeutics under Development by Companies
  • Skin Inflammation - Therapeutics under Investigation by Universities/Institutes
  • Skin Inflammation - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Skin Inflammation - Products under Development by Companies
  • Skin Inflammation - Products under Investigation by Universities/Institutes
  • Skin Inflammation - Companies Involved in Therapeutics Development
    • Med Discovery SA
    • Kineta, Inc.
    • Neopharm Co., Ltd.
    • vida therapeutics inc.
  • Skin Inflammation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ShK-186 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MDPK-67b - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MSX-122 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • V-2248 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OA-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NPS-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NPS-4 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Skin Inflammation - Recent Pipeline Updates
  • Skin Inflammation - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Skin Inflammation, H1 2014
  • Number of Products under Development for Skin Inflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Comparative Analysis by Unknown Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Skin Inflammation - Pipeline by Med Discovery SA, H1 2014
  • Skin Inflammation - Pipeline by Kineta, Inc., H1 2014
  • Skin Inflammation - Pipeline by Neopharm Co., Ltd., H1 2014
  • Skin Inflammation - Pipeline by vida therapeutics inc., H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Skin Inflammation Therapeutics - Recent Pipeline Updates, H1 2014
  • Skin Inflammation - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Skin Inflammation, H1 2014
  • Number of Products under Development for Skin Inflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top